Compare Stocks: PBH, CRNX, LNTH, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$156.70 +0.6%	$156.66	$62.18 ▼ $200.00	$6.27B	-1.23	165,790 shs	114,135 shs
CRNX Crinetics Pharmaceuticals	$84.95	$75.95	$30.25 ▼ $85.01	$9.01B	0.08	2.57 million shs	8.20 million shs
LNTH Lantheus	$100.88 -0.1%	$103.53	$49.67 ▼ $111.86	$6.59B	-0.03	1.79 million shs	1.38 million shs
PBH Prestige Consumer Healthcare	$52.85 +2.1%	$50.48	$42.62 ▼ $71.07	$2.45B	0.33	529,964 shs	592,569 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+0.64%	-3.08%	-1.20%	+14.19%	+148.61%
CRNX Crinetics Pharmaceuticals	0.00%	+0.11%	+1.71%	+156.72%	+174.12%
LNTH Lantheus	-0.08%	+0.01%	+1.24%	+0.63%	+83.75%
PBH Prestige Consumer Healthcare	+2.01%	+2.86%	+5.09%	+16.34%	-22.40%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$156.70 +0.6%	$156.66	$62.18 ▼ $200.00	$6.27B	-1.23	165,790 shs	114,135 shs
CRNX Crinetics Pharmaceuticals	$84.95	$75.95	$30.25 ▼ $85.01	$9.01B	0.08	2.57 million shs	8.20 million shs
LNTH Lantheus	$100.88 -0.1%	$103.53	$49.67 ▼ $111.86	$6.59B	-0.03	1.79 million shs	1.38 million shs
PBH Prestige Consumer Healthcare	$52.85 +2.1%	$50.48	$42.62 ▼ $71.07	$2.45B	0.33	529,964 shs	592,569 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+0.64%	-3.08%	-1.20%	+14.19%	+148.61%
CRNX Crinetics Pharmaceuticals	0.00%	+0.11%	+1.71%	+156.72%	+174.12%
LNTH Lantheus	-0.08%	+0.01%	+1.24%	+0.63%	+83.75%
PBH Prestige Consumer Healthcare	+2.01%	+2.86%	+5.09%	+16.34%	-22.40%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.63	Moderate Buy	$205.80	31.33% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.65% Downside
LNTH Lantheus	2.29	Hold	$108.11	7.17% Upside
PBH Prestige Consumer Healthcare	2.17	Hold	$70.75	33.87% Upside

Current Analyst Ratings Breakdown

Latest PBH, CRNX, LNTH, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/18/2026	BLTE Belite Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/14/2026	BLTE Belite Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$201.00 ➝ $206.00
8/14/2026	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$220.00
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/12/2026	BLTE Belite Bio	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$266.00 ➝ $270.00
8/12/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$200.00 ➝ $214.00
8/10/2026	PBH Prestige Consumer Healthcare	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform

(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$19.28 per share	N/A
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
LNTH Lantheus	$1.54B	4.27	$6.38 per share	15.81	$20.10 per share	5.02
PBH Prestige Consumer Healthcare	$1.09B	2.30	$5.32 per share	9.94	$40.46 per share	1.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	172.20	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.37	18.65	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	14.80	10.38	1.62	15.57%	11.39%	5.66%	11/5/2026 (Estimated)

Latest PBH, CRNX, LNTH, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
LNTH Lantheus	0.43	3.06	2.89
PBH Prestige Consumer Healthcare	1.06	3.23	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CRNX Crinetics Pharmaceuticals	98.51%
LNTH Lantheus	99.06%
PBH Prestige Consumer Healthcare	99.95%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CRNX Crinetics Pharmaceuticals	3.80%
LNTH Lantheus	1.70%
PBH Prestige Consumer Healthcare	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	40.27 million	34.92 million	Not Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.04 million	Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
PBH Prestige Consumer Healthcare	540	47.38 million	46.66 million	Optionable

PBH, CRNX, LNTH, and BLTE Headlines

Recent News About These Companies

Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test

September 1 at 9:18 AM | prnewswire.com

Bank of New York Mellon Corp Invests $15.38 Million in Prestige Consumer Healthcare Inc. $PBH

September 1 at 3:35 AM | marketbeat.com

Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Price Target at $70.75

August 31 at 4:11 AM | americanbankingnews.com

Man Group plc Buys Shares of 119,056 Prestige Consumer Healthcare Inc. $PBH

August 30 at 5:12 AM | marketbeat.com

Q2 Earnings Estimate for PBH Issued By Zacks Research

August 29, 2026 | americanbankingnews.com

PBH vs. SYK: Which Stock Is the Better Value Option?

August 28, 2026 | zacks.com

North Star Asset Management Inc. Invests $9.83 Million in Prestige Consumer Healthcare Inc. $PBH

August 28, 2026 | marketbeat.com

658,659 Shares in Prestige Consumer Healthcare Inc. $PBH Bought by The Manufacturers Life Insurance Company

August 28, 2026 | marketbeat.com

Deutsche Bank AG Takes Position in Prestige Consumer Healthcare Inc. $PBH

August 28, 2026 | marketbeat.com

What is Zacks Research's Forecast for PBH Q2 Earnings?

August 27, 2026 | marketbeat.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of "Hold" from Brokerages

August 26, 2026 | marketbeat.com

BlackRock Inc. Invests $370.19 Million in Prestige Consumer Healthcare Inc. $PBH

August 26, 2026 | marketbeat.com

49,241 Shares in Prestige Consumer Healthcare Inc. $PBH Acquired by Emerald Investment Advisers LLC

August 23, 2026 | marketbeat.com

Analysts Offer Insights on NA Companies: Springer Nature AG & Co. KGaA (OtherSPGDF) and Prestige Consumer Healthcare (PBH)

August 22, 2026 | theglobeandmail.com

Nearly 40,000 eye drops recalled nationwide over possible contamination

August 21, 2026 | foxbusiness.com

Great Lakes Advisors LLC Takes $2.98 Million Position in Prestige Consumer Healthcare Inc. $PBH

August 21, 2026 | marketbeat.com

Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts

August 18, 2026 | seekingalpha.com

Rice Hall James & Associates LLC Acquires Shares of 689,692 Prestige Consumer Healthcare Inc. $PBH

August 18, 2026 | marketbeat.com

Prestige Consumer Healthcare Announces Operations Leadership Transition

August 14, 2026 | tipranks.com

Here's why Prestige Consumer Healthcare (PBH) is a strong value stock

August 14, 2026 | msn.com

Prestige Consumer Healthcare (PBH) Q1 2027 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, CRNX, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$156.70 +0.99 (+0.64%)

As of 09/1/2026 04:00 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 08/31/2026 04:00 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Lantheus NASDAQ:LNTH

$100.88 -0.08 (-0.08%)

As of 09/1/2026 04:00 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Prestige Consumer Healthcare NYSE:PBH

$52.85 +1.07 (+2.07%)

As of 09/1/2026 03:58 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, CRNX, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, CRNX, LNTH, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, CRNX, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, CRNX, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Lantheus NASDAQ:LNTH

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PBH, CRNX, LNTH, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PBH, CRNX, LNTH, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PBH, CRNX, LNTH, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBH, CRNX, LNTH, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Lantheus NASDAQ:LNTH

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools